NMN: A Specific Metabolic Finding
AXON Research Institute • AXON Peptide affiliation
Educational draft • Scientific + legal review pending
Silent film with full on-screen captions. Conceptual illustrations, not molecular structures.

NMN, nicotinamide mononucleotide, is a precursor used in NAD+ metabolism. It is a small molecule, and its evidence should remain separate from peptide research. A ten-week randomized trial studied postmenopausal women with prediabetes who had overweight or obesity. The study examined specific metabolic outcomes rather than lifespan. Researchers reported improved muscle insulin sensitivity with NMN, while body composition did not change. A physiological measurement and a visible body transformation are different outcomes. This small, short study cannot settle long-term health benefits or safety. Its findings should not be generalized to everyone or described as proven anti-aging.

END CARD
Educational draft. Not medical advice. Sources and limitations accompany this film.

SOURCES
[1] Yoshino et al. (2021): Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
https://pmc.ncbi.nlm.nih.gov/articles/PMC8550608/
Primary randomized placebo-controlled human trial

EVIDENCE LIMITATIONS
The population was restricted and the trial small.
Muscle insulin sensitivity is a physiological endpoint, not evidence of longer life or disease prevention.
Do not generalize a studied preparation to all NMN products or routes.

TOPIC INVENTORY PROVENANCE (not reused audiovisual media)
NMN: What NAD-Precursor Studies Actually Measure